U
Ulrich T. Hopt
Researcher at University of Freiburg
Publications - 349
Citations - 11279
Ulrich T. Hopt is an academic researcher from University of Freiburg. The author has contributed to research in topics: Pancreatitis & Pancreas. The author has an hindex of 50, co-authored 347 publications receiving 10112 citations. Previous affiliations of Ulrich T. Hopt include University Medical Center Freiburg.
Papers
More filters
Journal ArticleDOI
[S3-guideline exocrine pancreatic cancer].
Thomas Seufferlein,M. Porzner,Thomas Becker,V. Budach,Güralp O. Ceyhan,Irene Esposito,Rainer Fietkau,M. Follmann,Helmut Friess,Peter R. Galle,M. Geißler,Matthias Glanemann,Thomas M. Gress,Volker Heinemann,W. Hohenberger,Ulrich T. Hopt,Jakob R. Izbicki,Ernst Klar,Jörg Kleeff,I. Kopp,Frank Kullmann,T. Langer,Jan M. Langrehr,Markus M. Lerch,Matthias Löhr,Jutta Lüttges,Manfred P. Lutz,Julia Mayerle,Patrick Michl,P. Möller,M. Molls,Marc W. Münter,M. Nothacker,Helmut Oettle,Stefan Post,Anke Reinacher-Schick,Christoph Röcken,Elke Roeb,H. Saeger,RM Schmid,Wolff Schmiegel,Michael H. Schoenberg,Jens T. Siveke,Martin Stuschke,Andrea Tannapfel,Waldemar Uhl,Susanne Unverzagt,B. van Oorschot,Y. Vashist,Jens Werner,Emre F. Yekebas +50 more
Journal ArticleDOI
Nonoperative treatment of 15 benign esophageal perforations with self-expandable covered metal stents.
TL;DR: Immediate insertion of a self-expandable metal stent enables an excellent outcome with minimal mortality and morbidity without the need for operation, even in cases of old esophageal perforations.
Journal ArticleDOI
ZEB1-associated drug resistance in cancer cells is reversed by the class I HDAC inhibitor mocetinostat
Simone Meidhof,Simone Brabletz,Waltraut Lehmann,Bogdan-Tiberius Preca,Kerstin Mock,Manuel Ruh,Julia Schüler,Maria Berthold,Anika Weber,Ulrike Burk,Michael Lübbert,Michael Lübbert,Martin Puhr,Zoran Culig,Ulrich F. Wellner,Tobias Keck,Peter Bronsert,Simon Küsters,Ulrich T. Hopt,Marc P. Stemmler,Thomas Brabletz,Thomas Brabletz +21 more
TL;DR: The data encourage the application of mechanism‐based combinations of selected epigenetic drugs with standard chemotherapy for the rational treatment of aggressive solid tumors, such as pancreatic cancer.
Journal ArticleDOI
Postoperative morbidity and long-term survival after pancreaticoduodenectomy with superior mesenterico-portal vein resection
TL;DR: After PD, perioperative morbidity and long-term survival in patients with SM-PVR were similar to those of patients without vein resection, and combined resection of the pancreatic head and the vein should always be considered in the absence of other contraindications for resection.
Journal ArticleDOI
Risk factors for complications after pancreatic head resection
TL;DR: Complication rate, duration of surgery, amount of blood transfused, and length of hospital stay decreased during the study period, and patients with risk factors should be considered for transferal to specialized centers.